Activated Clotting Time and Outcomes during Percutaneous Coronary Intervention for Non-ST-Segment-Elevation Myocardial Infarction

Circulation: Cardiovascular Interventions

Volumn 8, Issue 4, 2015, Pages

  Ducrocq, Gregory ^a,b   Jolly, Sanjit ^c   Mehta, Shamir R ^c   Rao, Sunil V ^d   Patel, Tejas ^e   Moreno, Raul ^f   Gao, Peggy ^c   Steg, Philippe Gabriel ^a,b,g  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c MCMASTER UNIVERSITY   (Canada)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e Apex Heart Institute   (India)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

angioplasty; hemorrhage; heparin; myocardial infarction; thrombosis

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; POLYSACCHARIDE;

ACTIVATED CLOTTING TIME; ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DEATH; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POLYSACCHARIDES; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; THROMBOSIS; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 84937400619     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002044     Document Type: Article

References (16)

1. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D; Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I. Guidelines on myocardial revascularization. Eur Heart J. 2010; 31:2501-2555.
2. Desai NR, Peterson ED, Chen AY, Wiviott SD, Sabatine MS, Alexander KP, Roe MT, Shah BR. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients-a report from the National Cardiovascular Data Registry. Am Heart J. 2013;166:1043-1049. e1. Doi: 10. 1016/j. Ahj. 2013. 09. 004.
3. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet. 1999; 353:429-438.
4. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX; CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-555. Doi: 10. 1161/CIR. 0b013e3182742c84.
5. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061-1065.
6. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
7. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003;41:386-393.
8. Bertrand OF, Rodés-Cabau J, Rinfret S, Larose E, Bagur R, Proulx G, Gleeton O, Costerousse O, De Larochellière R, Roy L. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol. 2009;104:1235-1240. Doi: 10. 1016/j. Amjcard. 2009. 06. 036.
9. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994-998. Doi: 10. 1161/01. CIR. 0000139868. 53594. 24.
10. Rozenman Y, Mehran R, Witzenbichler B, Dangas G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Stone GW. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. Catheter Cardiovasc Interv. 2013;81:E9-E14. Doi: 10. 1002/ccd. 24279.
11. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, López-Sendón JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S; FUTURA/OASIS-8 Trial Group. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339-1349. Doi: 10. 1001/jama. 2010. 1320.
12. Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Chrolavicius S, Rao SV, Granger CB, Pogue J, Laing S, Yusuf S. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010;160:1029-1034, 1034. e1. Doi: 10. 1016/j. Ahj. 2010. 07. 037.
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. Doi: 10. 1161/ CIRCULATIONAHA. 106. 685313.
14. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21:2409-2419. Doi: 10. 1002/sim. 1047.
15. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815-1823.
16. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054. Doi: 10. 1093/eurheartj/ehr236.